Bristol Myers Squibb drug shows promise in adolescent heart trial

March 29, 2026 11:45 AM

Bristol Myers Squibb (NYSE: BMY) announced positive results from its Phase 3 SCOUT-HCM trial evaluating Camzyos (mavacamten) in adolescents with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found